Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies

• Published in: Chinese medical journal Vol. 136; no. 2; pp. 230 - 232
• Main Authors: Deng, Zhenan, Jin, Meiling, Ou, Changxing, Jiang, Wei, Zhao, Jianping, Liu, Xiaoxia, Sun, Shenghua, Tang, Huaping, He, Bei, Cai, Shaoxi, Chen, Ping, Wu, Penghui, Liu, Yujing, Kang, Jian, Zhang, Yunhui, Huang, Mao, Xu, Jinfu, Huang, Kewu, Li, Qiang, Zhang, Xiangyan, Fu, Xiuhua, Wang, Changzheng, Shen, Huahao, Zhu, Lei, Shi, Guochao, Qiu, Zhongmin, Wen, Zhongguang, Wei, Xiaoyang, Gu, Wei, Wei, Chunhua, Wang, Guangfa, Xie, Lixin, Lin, Jiangtao, Tang, Yuling, Han, Zhihai, Chung, Kian Fan, Zhang, Qingling, Zhong, Nanshan
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 20.01.2023; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Antibodies; Asthma; Asthma - drug therapy; Biological Therapy; Biomarkers; Conflicts of interest; Correspondence; Genotype & phenotype; Humans; Respiratory diseases; China
• ISSN: 2542-5641; 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002556

Patients not eligible for any biologic treatments were characterized by the highest FeNO (33.2 ppb, P < 0.001), with raised sputum eosinophils and BEC (270/μL) and none received OCS therapy. Because the UK National Health and Care Institute has advocated the use of these biologics using different criteria (https://www.nice.org.uk/guidance/TA751/chapter/1-Recommendations), we have examined these conditions such as the need for having more than four severe exacerbations in the previous year and the combination of BEC ≥150/μL plus FeNO ≥25 ppb for consideration of severe asthma patients for anti-IL4Rα. [...]extending the cut-off point of 1, 2, 3, or 4 exacerbations in the previous year, those eligible for the biologic therapies would be 58.8%, 38.5%, 23.0%, and 15.3%, respectively [Supplementary Table 1, http://links.lww.com/CM9/B402]. [...]many of the 42.0% of severe asthma patients not eligible for biologic therapies represent those who do not report two or more exacerbations in the previous year, particularly in those with atopy and high BECs. [...]this study reveals that T2-high asthma is the predominant phenotype in patients with severe asthma in the C-BIOPRED cohort and remains relatively stable after a 1-year longitudinal visit.